TDC
ACHN

Thompson Davis & Co’s Achillion Pharmaceuticals ACHN Stock Holding History

Thompson Davis & Co’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-250
Closed -$2K – 1311
2014
Q3 		$2K Buy
+250
New +$2.32K ﹤0.01% 1078

Other funds holding ACHN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Thompson Davis & Co's ACHN Position: Q4 2014 in Review

Thompson Davis & Co sold out of Achillion Pharmaceuticals (ACHN) in Q4 2014, closing a stake of 250 shares — an estimated $2K sold.

Thompson Davis & Co first reported a position in ACHN in Q3 2014 and held it in 1 quarter. The position peaked at $2K in Q3 2014. 179 funds tracked by Wall St. Rank hold ACHN as of Q4 2014.

  • Thompson Davis & Co reported no remaining Achillion Pharmaceuticals position as of Q4 2014 after selling out during the quarter.
  • Thompson Davis & Co sold 250 Achillion Pharmaceuticals shares in Q4 2014, an estimated $2K.
  • Thompson Davis & Co first reported a position in Achillion Pharmaceuticals in Q3 2014 and held it in 1 quarter.
  • Thompson Davis & Co's Achillion Pharmaceuticals position peaked at $2K in Q3 2014.
  • 179 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q4 2014.

Based on Thompson Davis & Co's 13F filing for Q4 2014, filed 6 Feb 2015.